Abemaciclib and Nelfinavir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nelfinavir
Abemaciclib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Nelfinavir (Viracept) is a strong blocker of a liver enzyme called CYP3A4, which is the same enzyme your body uses to break down abemaciclib (Verzenio). When that enzyme is blocked, abemaciclib and its active form can build up higher than usual in your blood.
That extra buildup can mean more side effects, like diarrhea, low blood counts, or feeling very tired. This is based on how these drugs are expected to behave, not on lots of hard data, so please don't panic. The good news is your care team can manage this easily, often by lowering your abemaciclib dose while you're on both.
Mechanism: Nelfinavir is a strong CYP3A4 inhibitor; abemaciclib is a CYP3A4 substrate (active drug, not a prodrug). Inhibition reduces abemaciclib metabolism, increasing plasma exposure of abemaciclib and its active metabolites and raising toxicity risk (diarrhea, neutropenia, hepatotoxicity, fatigue).
- Direction: increased abemaciclib effect/exposure
- Evidence: theoretical; onset unspecified
- Management: If starting dose was 200 mg or 150 mg BID, reduce to 100 mg BID. If already reduced to 100 mg BID for adverse reactions, reduce to 50 mg BID. On inhibitor discontinuation, resume the pre-inhibitor dose after 3 to 5 inhibitor half-lives.
- Monitor for CBC changes, LFTs, and GI toxicity.
What happens
Increased abemaciclib plasma concentration
Interaction Deep Dive
Taking abemaciclib together with a potent CYP3A4 inhibitor can raise plasma concentrations of both abemaciclib and its active metabolite, potentially heightening toxicity. When these agents are given together and abemaciclib was started at either 200 mg or 150 mg twice daily, lower the abemaciclib dose to 100 mg twice daily. For patients whose dose has already been cut to 100 mg twice daily because of adverse reactions, decrease abemaciclib further to 50 mg twice daily. Once the strong CYP3A inhibitor is stopped, wait 3-5 half-lives of that inhibitor and then raise abemaciclib back to the dose that was in place prior to starting the strong inhibitor1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated abemaciclib metabolism
How to manage this interaction
This is manageable with dose planning and monitoring. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise.
- Your oncology team will typically lower the abemaciclib dose while you are on nelfinavir. If you were on 200 mg or 150 mg twice daily, the dose is usually reduced to 100 mg twice daily; if you were already at 100 mg twice daily, it may go to 50 mg twice daily.
- When nelfinavir is stopped, your team can raise abemaciclib back to your earlier dose after the nelfinavir clears.
- Tell your team promptly about diarrhea, unusual tiredness, fever, or signs of infection.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) Drug interaction studies predict that taking abemaciclib together with itraconazole (a strong CYP3A inhibitor) will raise the AUC of abemaciclib along with its active metabolites (M2, M18 and M20) by 2.2-fold 1.
b) In drug interaction studies conducted in cancer patients, giving a single 50 mg dose of abemaciclib (0.3 times the approved 150 mg dosage) alongside clarithromycin 500 mg twice daily (a strong CYP3A inhibitor) raised the AUC(0 to infinity) of abemaciclib together with its active metabolites (M2, M18, and M20) by 1.7-fold relative to abemaciclib given alone 1.
Common questions
Can I take Abemaciclib and Nelfinavir together?
Nelfinavir can raise abemaciclib levels and side effects, so your care team will usually lower the abemaciclib dose while you take both and adjust it back later. Keep taking both as prescribed and report new diarrhea, fatigue, or fever. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abemaciclib and Nelfinavir interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abemaciclib and Nelfinavir interaction managed?
This is manageable with dose planning and monitoring. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Your oncology team will typically lower the abemaciclib dose while you are on nelfinavir. If you were on 200 mg or 150 mg twice daily, the dose is usually reduced to 100 mg twice daily; if you were already at 100 mg twice daily, it may go to 50 mg twice… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abemaciclib or Nelfinavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: VERZENIO(TM) oral tablets, abemaciclib oral tablets. Lilly USA LLC (per FDA), Indianapolis, IN, 2017. DailyMed
Keep reading about Nelfinavir
Keep reading about Abemaciclib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist